{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-23-000075","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.734008+00:00","generated_at":"2026-06-12T02:13:06.421605+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas Q2 net loss $66.6M; vepdegestrant Phase 3 trials continue; ARV-766 shows 42% PSA50","bullets":["Net loss $66.6M vs $70.0M YoY; revenue $54.5M (up from $33.8M) from collaboration agreements.","Cash & securities $1,044.3M; expected to fund operations into 2026.","VERITAC-2 (2L) and VERITAC-3 (1L) Phase 3 trials of vepdegestrant enrolling; first Phase 3 data expected 2H 2024.","ARV-766 interim data: 42% PSA50 in AR LBD-mutant mCRPC patients; well-tolerated.","John Houston named Chairperson; Sunil Agarwal appointed to Board; cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-23-000075","json":"https://secwatch.observer/filing/0001655759-23-000075.json","markdown":"https://secwatch.observer/filing/0001655759-23-000075.md","text":"https://secwatch.observer/filing/0001655759-23-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000075/0001655759-23-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000075/arvn-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:13:06.421605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb874298cb4f1261e48a43d471debbd4efcf838a","claim":"ARVINAS, INC. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Arvinas, Inc. announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000075/0001655759-23-000075-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}